Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Wesseling, Jelle"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-20 z 20
    Tytuł:
    Microcalcification crystallography as a potential marker of DCIS recurrence.
    Autorzy:
    Gosling SB; School of Chemical and Physical Sciences, Keele University, Keele, UK. .
    Arnold EL; Cranfield Forensic Institute, Cranfield University, Shrivenham, UK.
    Davies SK; Cranfield Forensic Institute, Cranfield University, Shrivenham, UK.
    Cross H; School of Chemical and Physical Sciences, Keele University, Keele, UK.
    Bouybayoune I; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
    Calabrese D; School of Physics and Astronomy, University of Exeter, Exeter, UK.
    Nallala J; School of Physics and Astronomy, University of Exeter, Exeter, UK.
    Pinder SE; School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
    Fu L; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    King L; Department of Surgery, Duke University Medical Center, Durham, NC, UK.
    Marks J; Department of Surgery, Duke University Medical Center, Durham, NC, UK.
    Hall A; Department of Pathology, University of British Colombia, Vancouver, BC, Canada.
    Grimm LJ; Department of Radiology, Duke University, Durham, NC, UK.
    Lynch T; Department of Surgery, Duke University Medical Center, Durham, NC, UK.
    Pinto D; DCIS411.com, San Diego, CA, USA.
    Stobart H; Independent Cancer Patients' Voice, London, UK.
    Hwang ES; Department of Surgery, Duke University Medical Center, Durham, NC, UK.
    Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Divisions of Diagnostic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
    Geraki K; Diamond Light Source, Harwell Science and Innovation Campus, Didcot, UK.
    Stone N; School of Physics and Astronomy, University of Exeter, Exeter, UK.
    Lyburn ID; Cranfield Forensic Institute, Cranfield University, Shrivenham, UK.; Thirlestaine Breast Centre, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, Gloucestershire, UK.; Cobalt Medical Charity, Cheltenham, UK.
    Greenwood C; School of Chemical and Physical Sciences, Keele University, Keele, UK.
    Rogers KD; Cranfield Forensic Institute, Cranfield University, Shrivenham, UK. .
    Pokaż więcej
    Corporate Authors:
    Grand Challenge PRECISION Consortium
    Źródło:
    Scientific reports [Sci Rep] 2023 Jun 08; Vol. 13 (1), pp. 9331. Date of Electronic Publication: 2023 Jun 08.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Carcinoma, Intraductal, Noninfiltrating*/diagnostic imaging
    Carcinoma, Intraductal, Noninfiltrating*/pathology
    Carcinoma, Ductal, Breast*/pathology
    Calcinosis*/diagnostic imaging
    Calcinosis*/pathology
    Breast Neoplasms*/diagnostic imaging
    Breast Neoplasms*/pathology
    Humans ; Female ; Crystallography ; Neoplasm Recurrence, Local/pathology ; Tumor Microenvironment
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.
    Autorzy:
    Eijkelboom AH; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
    de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
    Vrancken Peeters MTFD; Department of Surgery, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Surgery, Amsterdam UMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    Broeders MJM; Department for Health Evidence, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.; Dutch Expert Centre for Screening, Wijchenseweg 101, 6538 SW, Nijmegen, The Netherlands.
    Strobbe LJA; Department of Surgical Oncology, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ, Nijmegen, The Netherlands.
    Bos MEMM; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
    Schmidt MK; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
    Guerrero Paez C; Dutch Breast Cancer Society (BVN), Godebaldkwartier 363, 3511 DT, Utrecht, The Netherlands.
    Smidt ML; Department of Surgery, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands.; GROW School for Oncology and Development Biology, Maastricht University, Univeristeitssingel 40, 6220 ER, Maastricht, the Netherlands.
    Bessems M; Department of Surgery, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, 's-Hertogenbosch, The Netherlands.
    Verloop J; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
    Linn S; Division of Diagnostic Oncology and Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
    Lobbes MBI; GROW School for Oncology and Development Biology, Maastricht University, Univeristeitssingel 40, 6220 ER, Maastricht, the Netherlands.; Department of Medical Imaging, Zuyderland Medical Center, Sittard-Geleen, Dr. H. van der Hoffplein 1, 6162 BG, Geleen, The Netherlands.; Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.
    Honkoop AH; Department of Medical Oncology, Isala Clinics, Dokter van Heesweg 2, 8025 AB, Zwolle, The Netherlands.
    van den Bongard DHJG; Department of Radiation Oncology, Amsterdam UMC, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    Westenend PJ; Laboratory of Pathology, Karel Lotsyweg 145, 3318 AL, Dordrecht, The Netherlands.
    Wesseling J; Division of Diagnostic Oncology and Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
    Menke-van der Houven van Oordt CW; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Location Vrije Universiteit Medical Centre, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
    Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Centre, P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.
    Siesling S; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. .; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands. .
    Pokaż więcej
    Corporate Authors:
    NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 17; Vol. 14 (1), pp. 64. Date of Electronic Publication: 2021 Apr 17.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms/*diagnosis
    Breast Neoplasms/*therapy
    Adult ; Aged ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; COVID-19/epidemiology ; Disease Management ; Female ; Humans ; Incidence ; Mass Screening ; Middle Aged ; Neoplasm Staging ; Netherlands/epidemiology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands.
    Autorzy:
    Dinmohamed AG; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. .; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. .; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. .
    Cellamare M; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
    Visser O; Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
    de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
    Elferink MAG; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands.
    Westenend PJ; Department of Pathology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.; Laboratory for Pathology Dordrecht, Dordrecht, The Netherlands.
    Wesseling J; Divisions of Diagnostic Oncology and Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
    Broeders MJM; Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Dutch Expert Centre for Screening, Nijmegen, The Netherlands.
    Kuipers EJ; Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
    Merkx MAW; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Department of Oral and Maxillofacial Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
    Nagtegaal ID; PALGA Foundation, Houten, The Netherlands.; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
    Siesling S; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. .; Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, The Netherlands. .
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2020 Nov 04; Vol. 13 (1), pp. 147. Date of Electronic Publication: 2020 Nov 04.
    Typ publikacji:
    Letter
    MeSH Terms:
    Breast Neoplasms/*diagnosis
    Colorectal Neoplasms/*diagnosis
    Adult ; Aged ; COVID-19/epidemiology ; Early Detection of Cancer ; Female ; Humans ; Mass Screening/statistics & numerical data ; Middle Aged ; Netherlands/epidemiology ; Pandemics
    Opinia redakcyjna
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping.
    Autorzy:
    Rontogianni S; 1Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.
    Synadaki E; 1Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.
    Li B; 1Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.
    Liefaard MC; 3Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Lips EH; 3Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Wesseling J; 3Division of Molecular Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.; 4Department of Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Wu W; 1Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.
    Altelaar M; 1Biomolecular Mass Spectrometry and Proteomics Group, Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, 3584 CH Utrecht, The Netherlands.; 5Mass Spectrometry and Proteomics Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
    Pokaż więcej
    Źródło:
    Communications biology [Commun Biol] 2019 Sep 03; Vol. 2, pp. 325. Date of Electronic Publication: 2019 Sep 03 (Print Publication: 2019).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms/*classification
    Breast Neoplasms/*metabolism
    Extracellular Vesicles/*metabolism
    Proteomics/*methods
    Animals ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/blood ; Breast Neoplasms/ultrastructure ; Cattle ; Cell Line, Tumor ; Extracellular Vesicles/ultrastructure ; Female ; Humans ; Neoplasm Proteins/metabolism ; Phosphoproteins/metabolism ; Principal Component Analysis ; Proteome/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.
    Autorzy:
    Beelen K; Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Opdam M; Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Severson T; Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Koornstra R; Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Vincent A; Departments of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Wesseling J; Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Sanders J; Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Vermorken J; Department of Medical Oncology, University Hospital Antwerpen, Edegem, Belgium.
    van Diest P; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
    Linn S; Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. .; Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands. .
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2018 Jul 24; Vol. 18 (1), pp. 761. Date of Electronic Publication: 2018 Jul 24.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Breast Neoplasms*/drug therapy
    Breast Neoplasms*/mortality
    Ki-67 Antigen*/analysis
    Ki-67 Antigen*/genetics
    Ki-67 Antigen*/metabolism
    Mitosis*/drug effects
    Mitosis*/physiology
    Antineoplastic Agents, Hormonal/*therapeutic use
    Tamoxifen/*therapeutic use
    Cell Proliferation ; Cluster Analysis ; Cyclin D1/genetics ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Middle Aged ; Postmenopause ; Retrospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.
    Autorzy:
    Sobral-Leite M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.
    Lips EH; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Vieira-Monteiro HA; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.; Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola Nacional de Saúde Pública-FIOCRUZ, Rio de Janeiro, RJ, Brasil.
    Giacomin LC; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.
    Freitas-Alves DR; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.; Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola Nacional de Saúde Pública-FIOCRUZ, Rio de Janeiro, RJ, Brasil.
    Cornelissen S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Mulder L; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Wesseling J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Schmidt MK; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Vianna-Jorge R; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.; Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola Nacional de Saúde Pública-FIOCRUZ, Rio de Janeiro, RJ, Brasil.; Programa de Farmacologia e Inflamação-Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2017 Dec 21; Vol. 12 (12), pp. e0189750. Date of Electronic Publication: 2017 Dec 21 (Print Publication: 2017).
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Polymorphism, Genetic*
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*genetics
    ErbB Receptors/*genetics
    Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Cohort Studies ; Female ; Genotype ; Humans
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    Autorzy:
    Schmitz AMT; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Radiology / Image Sciences Institute; University Medical Center Utrecht, Utrecht, Netherlands.
    Teixeira SC; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Pengel KE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Loo CE; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Vogel WV; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Wesseling J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Rutgers EJT; Department of Surgery, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Valdés Olmos RA; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Rodenhuis S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Vrancken Peeters MJTFD; Department of Surgery, The Netherlands Cancer Institute, Amsterdam, Netherlands.
    Gilhuijs KGA; Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands.; Department of Radiology / Image Sciences Institute; University Medical Center Utrecht, Utrecht, Netherlands.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2017 May 22; Vol. 12 (5), pp. e0176782. Date of Electronic Publication: 2017 May 22 (Print Publication: 2017).
    Typ publikacji:
    Comparative Study; Journal Article
    MeSH Terms:
    Breast Neoplasms/*diagnostic imaging
    Breast Neoplasms/*drug therapy
    Fluorodeoxyglucose F18/*metabolism
    Magnetic Resonance Imaging/*methods
    Positron Emission Tomography Computed Tomography/*methods
    Radiopharmaceuticals/*metabolism
    Adult ; Aged ; Breast Neoplasms/pathology ; Drug Therapy ; Female ; Humans ; Middle Aged ; Multimodal Imaging/methods ; Neoadjuvant Therapy ; Prospective Studies ; Receptor, ErbB-2/genetics ; Receptors, Estrogen/genetics ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
    Autorzy:
    Michaut M; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Chin SF; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
    Majewski I; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Severson TM; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Bismeijer T; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    de Koning L; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
    Peeters JK; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
    Schouten PC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Rueda OM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
    Bosma AJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Tarrant F; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland.
    Fan Y; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
    He B; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
    Xue Z; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Mittempergher L; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Kluin RJ; Genomic Core Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Heijmans J; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
    Snel M; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
    Pereira B; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
    Schlicker A; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Provenzano E; Cambridge Experimental Cancer Medicine Centre (ECMR) and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Cambridge Breast Unit and Cambridge University Hospitals, NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
    Ali HR; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.; Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QP, UK.
    Gaber A; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
    O'Hurley G; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland.
    Lehn S; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
    Muris JJ; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Kay E; Department of Pathology, RCSI ERC, Beaumont Hospital, Dublin 9, Ireland.
    Sammut SJ; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
    Bardwell HA; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
    Barbet AS; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
    Bard F; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
    Lecerf C; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
    O'Connor DP; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
    Vis DJ; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Benes CH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.
    McDermott U; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
    Garnett MJ; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
    Simon IM; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.
    Jirström K; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, SE-221 85 Lund, Sweden.
    Dubois T; Translational Research Department, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France.
    Linn SC; Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
    Gallagher WM; Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.; OncoMark Limited, NovaUCD, Belfield Innovation Park, Dublin 4, Ireland.
    Wessels LF; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Department of EEMCS, Delft University of Technology, Delft, The Netherlands.
    Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.; Cambridge Experimental Cancer Medicine Centre (ECMR) and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.; Cambridge Breast Unit and Cambridge University Hospitals, NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.; Department of Oncology, University of Cambridge, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
    Bernards R; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.; Agendia NV, Science Park 406, 1098 XH Amsterdam, The Netherlands.; Cancer Genomics Netherlands, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
    Pokaż więcej
    Źródło:
    Scientific reports [Sci Rep] 2016 Jan 05; Vol. 6, pp. 18517. Date of Electronic Publication: 2016 Jan 05.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Genomics*/methods
    Proteome*
    Transcriptome*
    Breast Neoplasms/*genetics
    Breast Neoplasms/*metabolism
    Carcinoma, Lobular/*genetics
    Carcinoma, Lobular/*metabolism
    Biomarkers, Tumor ; Breast Neoplasms/diagnosis ; Breast Neoplasms/mortality ; Carcinoma, Lobular/diagnosis ; Cluster Analysis ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Epithelial-Mesenchymal Transition/genetics ; Female ; Gene Expression Profiling ; Humans ; Immunohistochemistry ; Mutation Rate ; Polymorphism, Single Nucleotide ; Prognosis ; Proteomics ; Reproducibility of Results ; Transcription Factors/genetics ; Transcription Factors/metabolism
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.
    Autorzy:
    Jiwa LS
    van Diest PJ
    Hoefnagel LD
    Wesseling J
    Wesseling P
    Moelans CB; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, Utrecht 3508GA, The Netherlands. .
    Pokaż więcej
    Corporate Authors:
    Dutch Distant Breast Cancer Metastases Consortium
    Źródło:
    BMC cancer [BMC Cancer] 2014 Nov 22; Vol. 14, pp. 864. Date of Electronic Publication: 2014 Nov 22.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms/*metabolism
    Breast Neoplasms/*pathology
    Claudin-4/*metabolism
    Glucose Transporter Type 1/*metabolism
    Breast Neoplasms/genetics ; Claudin-4/genetics ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Glucose Transporter Type 1/genetics ; Humans ; Immunohistochemistry ; Neoplasm Metastasis ; Receptor, IGF Type 1/genetics ; Receptor, IGF Type 1/metabolism ; Up-Regulation
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
    Autorzy:
    Pengel KE; Department of Radiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE, Amsterdam, The Netherlands.
    Koolen BB
    Loo CE
    Vogel WV
    Wesseling J
    Lips EH
    Rutgers EJ
    Valdés Olmos RA
    Vrancken Peeters MJ
    Rodenhuis S
    Gilhuijs KG
    Pokaż więcej
    Źródło:
    European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2014 Aug; Vol. 41 (8), pp. 1515-24. Date of Electronic Publication: 2014 Apr 29.
    Typ publikacji:
    Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Magnetic Resonance Imaging*
    Multimodal Imaging*
    Positron-Emission Tomography*
    Tomography, X-Ray Computed*
    Breast Neoplasms/*diagnostic imaging
    Carcinoma, Ductal/*diagnostic imaging
    Adult ; Breast Neoplasms/diagnosis ; Breast Neoplasms/drug therapy ; Carcinoma, Ductal/diagnosis ; Carcinoma, Ductal/drug therapy ; Drug Therapy, Combination ; Female ; Fluorodeoxyglucose F18 ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Radiopharmaceuticals
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.
    Autorzy:
    Vollebergh MA; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Division of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
    Klijn C; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
    Schouten PC; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
    Wesseling J; Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
    Israeli D; Department of Pathology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.
    Ylstra B; Department of Pathology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.
    Wessels LF; Department of Bioinformatics and Statistics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, the Netherlands.
    Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
    Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands; Division of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
    Pokaż więcej
    Źródło:
    PloS one [PLoS One] 2014 Aug 01; Vol. 9 (8), pp. e103177. Date of Electronic Publication: 2014 Aug 01 (Print Publication: 2014).
    Typ publikacji:
    Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Genetic Heterogeneity*
    Breast Neoplasms/*genetics
    Breast Neoplasms/*pathology
    Lymph Nodes/*pathology
    Breast Neoplasms/metabolism ; Cluster Analysis ; Comparative Genomic Hybridization ; DNA Copy Number Variations ; Female ; Genomic Instability ; Genomics ; Humans ; Lymphatic Metastasis ; Prognosis ; Triple Negative Breast Neoplasms
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Genetic predisposition to in situ and invasive lobular carcinoma of the breast.
    Autorzy:
    Sawyer E; Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
    Roylance R; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
    Petridis C; Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
    Brook MN; Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
    Nowinski S; Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
    Papouli E; Biomedical Research Centre, King's College London, Guy's Hospital, London, United Kingdom.
    Fletcher O; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
    Pinder S; Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
    Hanby A; Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.
    Kohut K; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
    Gorman P; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
    Caneppele M; Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
    Peto J; London School of Hygiene and Tropical Medicine, London, United Kingdom.
    Dos Santos Silva I; London School of Hygiene and Tropical Medicine, London, United Kingdom.
    Johnson N; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
    Swann R; Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.
    Dwek M; Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.
    Perkins KA; Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.
    Gillett C; Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.
    Houlston R; Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
    Ross G; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
    De Ieso P; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
    Southey MC; Department of Pathology, The University of Melbourne, Melbourne, Australia.
    Hopper JL; Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
    Provenzano E; NIHR Cambridge Biomedical Research Centre, Addenbrookes Hospital, Cambridge, United Kingdom.
    Apicella C; Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
    Wesseling J; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
    Cornelissen S; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
    Keeman R; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
    Fasching PA; David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, United States of America; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
    Jud SM; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
    Ekici AB; Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
    Beckmann MW; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
    Kerin MJ; Surgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.
    Marme F; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
    Schneeweiss A; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.
    Sohn C; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.
    Burwinkel B; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Guénel P; Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.
    Truong T; Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.
    Laurent-Puig P; Université Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France.
    Kerbrat P; Centre Eugène Marquis, Department of Medical Oncology, Rennes, France.
    Bojesen SE; Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
    Nordestgaard BG; Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
    Nielsen SF; Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
    Flyger H; Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
    Milne RL; Genetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
    Perez JI; Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.
    Menéndez P; Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.
    Benitez J; Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
    Brenner H; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Dieffenbach AK; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Arndt V; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Stegmaier C; Saarland Cancer Registry, Saarbrücken, Germany.
    Meindl A; Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.
    Lichtner P; Institute of Human Genetics, Technische Universität, Munich, Germany.
    Schmutzler RK; Centre for Familial Breast and Ovarian Cancer and Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
    Lochmann M; Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.
    Brauch H; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.
    Fischer HP; Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany.
    Ko YD; Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.
    Nevanlinna H; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
    Muranen TA; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
    Aittomäki K; Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland.
    Blomqvist C; Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.
    Bogdanova NV; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
    Dörk T; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
    Lindblom A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
    Margolin S; Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.
    Mannermaa A; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
    Kataja V; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
    Kosma VM; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
    Hartikainen JM; School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
    Chenevix-Trench G; Department of Genetics, QIMR Berghofer Institute of Medical Research, Brisbane, Australia.
    Lambrechts D; Vesalius Research Center (VRC), VIB, Leuven, Belgium; Department of Oncology, University of Leuven, Leuven, Belgium.
    Weltens C; University Hospital Gashuisberg, Leuven, Belgium.
    Van Limbergen E; University Hospital Gashuisberg, Leuven, Belgium.
    Hatse S; University Hospital Gashuisberg, Leuven, Belgium.
    Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Rudolph A; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Seibold P; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Flesch-Janys D; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
    Radice P; Unit of Molecular Bases of Genetic Risk and Genetic Testing, Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.
    Peterlongo P; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.
    Bonanni B; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.
    Volorio S; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.
    Giles GG; Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
    Severi G; Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
    Baglietto L; Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.
    McLean CA; Department of Pathology, The Alfred Hospital, Prahran, Victoria, Australia.
    Haiman CA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
    Henderson BE; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
    Schumacher F; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.
    Le Marchand L; Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America.
    Simard J; Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.
    Goldberg MS; Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.
    Labrèche F; Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada.
    Dumont M; Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.
    Kristensen V; Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine (Faculty Division Ahus), UiO, Oslo, Norway.
    Winqvist R; Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.
    Pylkäs K; Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.
    Jukkola-Vuorinen A; Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.
    Kauppila S; Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.
    Andrulis IL; Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
    Knight JA; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
    Glendon G; Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
    Mulligan AM; Laboratory Medicine Program, University Health Network, Toronto, Ontario; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
    Devillee P; Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
    Tollenaar RA; Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
    Seynaeve CM; Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
    Kriege M; Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
    Figueroa J; Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.
    Chanock SJ; Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.
    Sherman ME; Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.
    Hooning MJ; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
    Hollestelle A; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
    van den Ouweland AM; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
    van Deurzen CH; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.
    Li J; Human Genetics Division, Genome Institute of Singapore, Singapore.
    Czene K; Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
    Humphreys K; Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
    Cox A; CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.
    Cross SS; Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom.
    Reed MW; CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.
    Shah M; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
    Jakubowska A; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
    Lubinski J; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
    Jaworska-Bieniek K; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.
    Durda K; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
    Swerdlow A; Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
    Ashworth A; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.
    Orr N; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.
    Schoemaker M; Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.
    Couch FJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.
    Hallberg E; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.
    González-Neira A; Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
    Pita G; Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
    Alonso MR; Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.
    Tessier DC; McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
    Vincent D; McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
    Bacot F; McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
    Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
    Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
    Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
    Michailidou K; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
    Dunning AM; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
    Hall P; Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
    Easton D; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
    Pharoah P; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
    Schmidt MK; Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
    Tomlinson I; Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
    Garcia-Closas M; Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.
    Pokaż więcej
    Corporate Authors:
    GENICA Network
    KConFab Investigators; Peter MacCallum Cancer Center, Melbourne, Australia.
    Źródło:
    PLoS genetics [PLoS Genet] 2014 Apr 17; Vol. 10 (4), pp. e1004285. Date of Electronic Publication: 2014 Apr 17 (Print Publication: 2014).
    Typ publikacji:
    Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    Breast Neoplasms/*genetics
    Carcinoma in Situ/*genetics
    Carcinoma, Lobular/*genetics
    Genetic Predisposition to Disease/*genetics
    Case-Control Studies ; Female ; Genome-Wide Association Study ; Genotype ; Humans ; Middle Aged ; Polymorphism, Single Nucleotide/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
    Autorzy:
    Koolen BB; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
    Pengel KE
    Wesseling J
    Vogel WV
    Vrancken Peeters MJ
    Vincent AD
    Gilhuijs KG
    Rodenhuis S
    Rutgers EJ
    Valdés Olmos RA
    Pokaż więcej
    Źródło:
    European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2014 Jan; Vol. 41 (1), pp. 32-40. Date of Electronic Publication: 2013 Aug 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Fluorodeoxyglucose F18*
    Neoadjuvant Therapy*
    Positron-Emission Tomography*
    Tomography, X-Ray Computed*
    Breast Neoplasms/*diagnosis
    Breast Neoplasms/*drug therapy
    Lymph Nodes/*drug effects
    Adult ; Aged ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; Lymph Nodes/pathology ; Middle Aged ; Multimodal Imaging ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Retrospective Studies ; Sensitivity and Specificity ; Time Factors ; Treatment Outcome ; Triple Negative Breast Neoplasms/diagnosis ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/pathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.
    Autorzy:
    Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. />Mandjes IA
    Holtkamp MJ
    Schot M
    van Werkhoven E
    Wesseling J
    Vrancken Peeters MJ
    Rodenhuis S
    Linn SC
    Pokaż więcej
    Źródło:
    The breast journal [Breast J] 2013 Jul-Aug; Vol. 19 (4), pp. 419-26. Date of Electronic Publication: 2013 May 20.
    Typ publikacji:
    Clinical Trial; Journal Article
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Breast Neoplasms/*drug therapy
    Adult ; Aged ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Carboplatin/administration & dosage ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neutropenia/chemically induced ; Paclitaxel/administration & dosage ; Receptor, ErbB-2/metabolism ; Remission Induction ; Thrombocytopenia/chemically induced ; Trastuzumab ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples.
    Autorzy:
    Zwart W; Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK. />Koornstra R
    Wesseling J
    Rutgers E
    Linn S
    Carroll JS
    Pokaż więcej
    Źródło:
    BMC genomics [BMC Genomics] 2013 Apr 08; Vol. 14, pp. 232. Date of Electronic Publication: 2013 Apr 08.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Breast Neoplasms/*pathology
    Chromatin/*metabolism
    Chromatin Immunoprecipitation/*methods
    Estrogen Receptor alpha/*metabolism
    Sequence Analysis/*methods
    Biopsy, Large-Core Needle ; Humans ; MCF-7 Cells ; Protein Binding
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
    Autorzy:
    Blows FM; Department of Oncology, University of Cambridge, United Kingdom.
    Driver KE
    Schmidt MK
    Broeks A
    van Leeuwen FE
    Wesseling J
    Cheang MC
    Gelmon K
    Nielsen TO
    Blomqvist C
    Heikkilä P
    Heikkinen T
    Nevanlinna H
    Akslen LA
    Bégin LR
    Foulkes WD
    Couch FJ
    Wang X
    Cafourek V
    Olson JE
    Baglietto L
    Giles GG
    Severi G
    McLean CA
    Southey MC
    Rakha E
    Green AR
    Ellis IO
    Sherman ME
    Lissowska J
    Anderson WF
    Cox A
    Cross SS
    Reed MW
    Provenzano E
    Dawson SJ
    Dunning AM
    Humphreys M
    Easton DF
    García-Closas M
    Caldas C
    Pharoah PD
    Huntsman D
    Pokaż więcej
    Źródło:
    PLoS medicine [PLoS Med] 2010 May 25; Vol. 7 (5), pp. e1000279. Date of Electronic Publication: 2010 May 25.
    Typ publikacji:
    Journal Article; Meta-Analysis
    MeSH Terms:
    Biomarkers, Tumor/*analysis
    Breast Neoplasms/*mortality
    ErbB Receptors/*analysis
    Hormones/*analysis
    Receptors, Cell Surface/*metabolism
    Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Humans ; Immunohistochemistry ; Keratins ; Middle Aged ; Prognosis ; Proportional Hazards Models ; Young Adult
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-20 z 20

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies